Could teriparatide be the treatment for osteonecrosis of the jaws?

Head and Neck

Volumn 33, Issue 9, 2011, Pages 1382-1383

  Kyrgidis, Athanassios ^a   Antoniades, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34];

ALEDRONATE INDUCED JAW OSTEONECROSIS; ALENDRONATE INDUCED JAW OSTEONECROSIS; AMINO TERMINAL SEQUENCE; BONE MASS; BONE STRENGTH; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; JAW OSTEONECROSIS; LETTER; MULTIPLE MYELOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; TERIPARATIDE;

EID: 80051713349     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21512     Document Type: Letter

References (11)

1. Lee J-J, Cheng S-J, Jeng J-H, Chiang C-P, Lau H-P, Kok S-H,. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 2010 doi: 10.1002/hed.21380 [Epub ahead of print]
2. Kyrgidis A, Koloutsos G, Vahtsevanos K,. Treatment protocols of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2009; 31: 1112-1113, 2009; author reply 1113-1114.
3. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-5362.
4. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J,. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 2010 [Epub ahead of print]
5. Solomon DH, Rekedal L, Cadarette SM,. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009; 21: 363-368.
6. Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006; 34: 929-940. (Pubitemid 46011145)
7. Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M,. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008; 23: 2033-2039.
8. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K,. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcified Tissue Int 2009; 84: 159-170.
9. Harper RP, Fung E,. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573-580. (Pubitemid 46343587)
10. Kyrgidis A, Verrou E,. Fatigue in bone: a novel phenomenon attributable to bisphosphonate use. Bone 2010; 46: 556; author reply 557-558.
11. Kyrgidis A, Vahtsevanos K,. "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Invest 2009; 13: 479-480.